<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00710697</url>
  </required_header>
  <id_info>
    <org_study_id>0701</org_study_id>
    <nct_id>NCT00710697</nct_id>
  </id_info>
  <brief_title>Cardiac Safety Assessment Study of Picoplatin in Solid Tumors</brief_title>
  <official_title>A Phase 1 Study of Picoplatin in Subjects With Advanced Non-Hematological Malignancies With Emphasis on Cardiac Repolarization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poniard Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poniard Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate what effects, if any, picoplatin has on the heart&#xD;
      rhythm.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1 and 2 studies have demonstrated that picoplatin, a next-generation platinum analogue&#xD;
      designed to avoid drug resistance, has activity when administered IV in a variety of cancers.&#xD;
      Preclinical and clinical studies indicate that picoplatin may be effective in platinum&#xD;
      refractory or resistant cancer.&#xD;
&#xD;
      Preclinical data in beagle dogs have shown that picoplatin had no effect on cardiovascular&#xD;
      function, including the QT interval. In the cumulative human trial experience, the&#xD;
      cardiovascular serious adverse events that have occurred are consistent with events expected&#xD;
      in patients with advanced malignant disease and do not suggest any propensity toward&#xD;
      drug-related serious ventricular arrhythmias or sudden death.&#xD;
&#xD;
      The purpose of this trial is to conduct a formal study to specifically evaluate the effect of&#xD;
      picoplatin on the QT/QTc interval as measured by the ECG, and to correlate QTcF interval with&#xD;
      plasma total and ultrafilterable platinum concentrations. This study is also being conducted&#xD;
      to ensure the safety of picoplatin with regard to the QT/QTc interval. Patients who choose to&#xD;
      participate in this study will also be given the opportunity to continue to receive&#xD;
      picoplatin until limited by toxicity or disease progression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2008</start_date>
  <completion_date type="Anticipated">July 2009</completion_date>
  <primary_completion_date type="Anticipated">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ECG interval change</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety/Efficacy</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Picoplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Picoplatin</intervention_name>
    <description>IV 150 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented histological or cytological diagnosis of non-hematological malignancy.&#xD;
&#xD;
          -  Subjects for whom, in the opinion of the investigator, treatment with single agent&#xD;
             picoplatin is appropriate.&#xD;
&#xD;
          -  18 years of age or older.&#xD;
&#xD;
          -  ECOG performance status 0-2.&#xD;
&#xD;
          -  An acceptable screening ECG.&#xD;
&#xD;
          -  The following laboratory values:&#xD;
&#xD;
          -  ANC ≥ 1500 cells/mm3 (without use of myeloid growth factors).&#xD;
&#xD;
          -  Hemoglobin ≥ 10.0 g/dL (may be achieved with transfusion or growth factors).&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm3 (without platelet transfusions in the past 10 days).&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 x ULN.&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 x ULN.&#xD;
&#xD;
          -  AST/SGOT and ALT/SGPT ≤ 2.5 x ULN (up to 5.0 x ULN in the event of documented hepatic&#xD;
             tumor involvement).&#xD;
&#xD;
          -  Serum potassium and magnesium within institutional normal limits. PT, aPTT ≤ 1.2 x&#xD;
             ULN.&#xD;
&#xD;
          -  Recovery period ≥ 4 weeks since major surgery, any chemotherapy (≥ 6 weeks for&#xD;
             treatment with mitomycin or any nitrosourea), any biological therapy, any&#xD;
             investigational therapy or any change in usage of &quot;alternative therapies&quot;.&#xD;
&#xD;
          -  Recovery period ≥ 2 weeks since any radiation therapy.&#xD;
&#xD;
          -  Willing, available and able to comply with all protocol requirements including dietary&#xD;
             schedule and restrictions.&#xD;
&#xD;
          -  Written informed consent obtained prior to any screening procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Symptomatic or uncontrolled brain metastases.&#xD;
&#xD;
          -  Use of conventional granulocyte growth factors within the preceding 10 days or&#xD;
             pegfilgrastim within the past 21 days.&#xD;
&#xD;
          -  Any concurrent severe and/or uncontrolled medical conditions which could compromise&#xD;
             participation in the study. For example,&#xD;
&#xD;
          -  Unresolved toxicities from prior treatments of &gt; Grade 1 (other than alopecia).&#xD;
&#xD;
          -  Clinically significant infection.&#xD;
&#xD;
          -  Known viral infections with hepatitis B or C or HIV.&#xD;
&#xD;
          -  Clinically significant psychiatric illness.&#xD;
&#xD;
          -  Any other systemic or localized disease or therapy likely to interfere with tolerance&#xD;
             of chemotherapy or requirements of study participation.&#xD;
&#xD;
          -  History of unexplained syncope within the last two months or a family history of&#xD;
             sudden unexplained death.&#xD;
&#xD;
          -  Cardiac contraindications to study participation, including:&#xD;
&#xD;
          -  History of serious cardiac disease, defined as myocardial infarction within three&#xD;
             months of enrollment, congestive heart failure classified by the New York Heart&#xD;
             Association as Class III or IV, clinically significant cardiac arrhythmias, poorly&#xD;
             controlled or unstable angina or electrocardiographic evidence of acute ischemia.&#xD;
&#xD;
          -  Implantable pacemaker or automatic implantable cardioverter defibrillator.&#xD;
&#xD;
          -  Congenital long QT syndrome or family history of long QT syndrome.&#xD;
&#xD;
          -  If male, QTc &gt; 450 ms; if female, QTc &gt; 460 ms.&#xD;
&#xD;
          -  PR duration &gt; 240 ms; QRS &gt; 110 ms. Complex arrhythmias (significant ventricular&#xD;
             tachycardia, Mobitz block, bifascicular AV block) on the screening ECG.&#xD;
&#xD;
          -  Atrial fibrillation or flutter. Complete left bundle branch block; use of an obligate&#xD;
             pacemaker.&#xD;
&#xD;
          -  Current use of anticoagulants or anti-platelet drugs, including aspirin, warfarin,&#xD;
             enoxaparin, clopidogrel, or heparin (use of heparin for central venous port&#xD;
             maintenance is acceptable).&#xD;
&#xD;
          -  Ongoing bleeding or history of clinically significant bleeding within the last 6&#xD;
             months (unless the etiology of the prior bleeding has been identified and corrected).&#xD;
&#xD;
          -  Concurrent medications that prolong the QT interval (including cisapride,&#xD;
             erythromycin, antipsychotics or tricyclic antidepressants, quinidine, procainamide,&#xD;
             disopyramide, amiodarone or sotalol), or any agent classified as either &quot;Drugs with&#xD;
             Risk of Torsades de Pointes&quot; or &quot;Drugs with Possible Risk of Torsades de Pointes&quot; on&#xD;
             the website www.torsades.org.&#xD;
&#xD;
          -  Female subjects who are pregnant or breast feeding.&#xD;
&#xD;
          -  Subjects of reproductive potential not willing to use an effective method of&#xD;
             contraception during the study (from first day of and until 1 month after study drug&#xD;
             administration).&#xD;
&#xD;
          -  Conditions that may interfere with QTc analysis:&#xD;
&#xD;
          -  Allergy to ECG electrodes.&#xD;
&#xD;
          -  Any condition that impairs the placement of ECG electrodes or the interpretation of&#xD;
             ECGs (including but not limited to breast implants).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Earhart, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Poniard Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Premiere Oncology of Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moores UCSD Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premiere Oncology</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Cancer Specialists</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNM Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialities</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.poniard.com/about/overview.html</url>
    <description>Sponsors website</description>
  </link>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>July 2, 2008</study_first_submitted>
  <study_first_submitted_qc>July 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2008</study_first_posted>
  <last_update_submitted>September 23, 2009</last_update_submitted>
  <last_update_submitted_qc>September 23, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2009</last_update_posted>
  <responsible_party>
    <name_title>Robert Earhart, MD, PhD</name_title>
    <organization>Poniard Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Bladder Cancer</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Gastrointestinal Neoplasm</keyword>
  <keyword>Head and Neck Cancer</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Pancreatic Cancer</keyword>
  <keyword>Prostrate Cancer</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

